Drug Profile


Alternative Names: Briciclib sodium; ON-013105; ON-014185

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Temple University
  • Developer Onconova Therapeutics
  • Class Antineoplastics; Phenols; Phenyl ethers; Small molecules; Sulfones
  • Mechanism of Action Cyclin D1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • No development reported Acute lymphoblastic leukaemia; Lymphoma

Most Recent Events

  • 09 Nov 2017 Phase I development in Solid-tumours (Metastatic disease) is ongoing in USA (IV, Infusion) (Onconova pipeline, November 2017)
  • 21 Sep 2017 Cellectar Biosciences and Onconova Therapeutics enter into a collaboration to develop phospholipid drug conjugates, including briciclib, for Cancer
  • 29 Mar 2017 Onconova Therapeutics has patent protection and pending patent applications for briciclib in USA and other countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top